A5023318958- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Cancer Treatment and Pharmacology
- Genetic factors in colorectal cancer
- BRCA gene mutations in cancer
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Treatments and Mutations
- Cancer, Lipids, and Metabolism
- Metastasis and carcinoma case studies
- PARP inhibition in cancer therapy
- HER2/EGFR in Cancer Research
- Sarcoma Diagnosis and Treatment
- Colorectal and Anal Carcinomas
- Colorectal Cancer Surgical Treatments
- Gastrointestinal Tumor Research and Treatment
- Cancer Immunotherapy and Biomarkers
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
- PI3K/AKT/mTOR signaling in cancer
- Multiple and Secondary Primary Cancers
- Renal cell carcinoma treatment
- Ovarian cancer diagnosis and treatment
- Pancreatic and Hepatic Oncology Research
- Inflammatory Biomarkers in Disease Prognosis
Azienda Ospedaliero Universitaria Ospedali Riuniti
2009-2022
Ospedali Riuniti di Ancona
2009-2022
Ospedali Riuniti Umberto I
2009-2021
Marche Polytechnic University
2010-2019
Hôpital Saint-André
2012
There is a growing body of evidence that immune response plays large role in cancer outcome. The neutrophil to lymphocyte ratio (NLR) has been used as simple parameter systemic inflammation several tumors. purpose was investigate the association between pre-treatment NLR, disease-free survival and overall patients with early triple negative breast (TNBC).We reviewed records stage I-III TNBC at our Institution from 2006 2012. NLR analyzed. difference among variables calculated by chi-square...
Lactate dehydrogenase (LDH) represents a predictive factor in colorectal cancer patients treated with the angiogenesis inhibitor PTK/ZK. We explored role of pre-treatment LDH serum levels receiving first-line bevacizumab.Metastatic bevacizumab was eligible. A control group including all consecutive chemotherapy alone also considered. Pre-treatment were collected for cases.Median progression-free survival (PFS) high and low 4.2 8 months, respectively (P=0.0003). Median overall (OS) 19.6 34.9...
Background: Triple-negative breast cancers (TNBC) are characterized by aggressive tumour biology resulting in a poor prognosis. Androgen receptor (AR) is one of newly emerging biomarker TNBC. In recent years, ARs have been demonstrated to play an important role the genesis and development cancer, although their prognostic still debated. present study, we explored correlation AR expression with clinical, pathological molecular features its impact on prognosis early Patients Methods: were...
Currently, sunitinib represents one of the therapeutic strongholds for renal cell carcinoma, but criteria treatment selection are lacking. We assessed role vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) polymorphisms in prediction clinical outcome metastatic carcinoma (mRCC) patients.A total 84 tumour samples from mRCC patients receiving first-line were tested VEGFR single-nucleotide (SNPs). The SNP results correlated with progression-free survival (PFS) overall...
In many tumor types serum lactate dehydrogenase (LDH) levels is an indirect marker of hypoxia, neo-angiogenesis and worse prognosis. However data about hepatocellular carcinoma (HCC) are lacking in the clinical setting patients undergoing transarterial-chemoembolization (TACE) whom hypoxia may represent a molecular key to treatment failure. Aim our analysis was evaluate role LDH pre-treatment determining outcome for with HCC receiving TACE. One hundred fourteen were available analysis. For...
Abstract Regorafenib monotherapy is a potential option for metastatic colorectal cancer patients. However, the lack of predictive factors and severe toxicities related to treatment have made its use in clinical practice challenging. Polymorphisms VEGF receptor (VEGFR) genes might regulate angiogenesis thus potentially influence outcome during anti-angiogenesis such as regorafenib. Aim our study was evaluate role VEGFR genotyping determining patients receiving We retrospectively collected...
// Elena Maccaroni 1 , Raffaella Bracci Riccardo Giampieri Francesca Bianchi Laura Belvederesi Cristiana Brugiati Silvia Pagliaretta Michela Del Prete Mario Scartozzi 2 Stefano Cascinu Clinica di Oncologia Medica e Centro Regionale Genetica Oncologica, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti, Ancona, Italy Medical Oncology, Cagliari, Monserrato (CA), Correspondence to: Bracci, e-mail: raffaellabracci@libero.it Keywords: Lynch syndrome, germline...
Clinical observations suggested that a non negligible proportion of patients, ranging from 40% to 70%, does not seem benefit the use anti-EGFR targeted antibodies even in absence mutation K- RAS gene. The EGFR pathway activation via Ras-Raf-MAP-kinase and protein-serine/threonine kinase AKT could determine resistance treatment. We tested interaction between phosphorylated MAPK expression colorectal tumours corresponding metastases global outcome K-RAS wild type patients receiving...
Abstract Regorafenib is an orally administered multikinase inhibitor indicated for the treatment of heavily pretreated metastatic colorectal cancer patients with good performance status, albeit less than 50% treated achieve disease stabilisation or better at first radiological evaluation. In addition to that a particularly broad spectrum toxicities (experienced as G3 more NCI CTCAE graded by treated) have led reconsider its widespread use in majority patients. We retrospectively collected...